All Stories

  1. Association between Public Reporting of Outcomes and the Use of Mechanical Circulatory Support in Patients with Cardiogenic Shock
  2. Non-Cardiovascular Comorbidities as Evaluated by Elixhauser Comorbidity Score in Individuals Undergoing TAVR
  3. Cardiorespiratory Stability of Patients Undergoing Transcatheter Aortic Valve Replacement Is Not Improved During General Anesthesia Compared to Sedation: A Retrospective, Observational Study
  4. Balloon Mitral Valvuloplasty in the United States: A 13-Year Perspective
  5. Percutaneous Aortic Balloon Valvotomy in the United States: A 13-Year Perspective
  6. The association between body mass index and coronary artery disease severity: A comparison of black and white patients
  7. CHOLESTERYL ESTER TRANSFER PROTEIN LEVELS AND CALCIUM SCORE AS RISK PREDICTORS OF CARDIOVASCULAR OUTCOMES
  8. ONE YEAR OUTCOME AFTER PERCUTANEOUS CLOSURE OF PARAVALVULAR LEAKS OF EDWARDS-SAPIEN TRANSCATHETER AORTIC VALVE
  9. DRUG-ELUTING STENTS ARE STILL UNDERUSED IN GOVERNMENT INSURANCE AND UNINSURED: A META-ANALYSIS
  10. NOTCH1 IS ASSOCIATED WITH THE DEVELOPMENT OF TRI-LEAFLET CALCIFIC AORTIC STENOSIS
  11. TRANSCATHETER AORTIC VALVE REPLACEMENT VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN A LOW TO INTERMEDIATE RISK POPULATION
  12. COMBINED USE OF UNBOUND FREE FATTY ACID AND MYOGLOBIN PREDICTS ADVERSE OUTCOMES IN NON-ST ELEVATION ACUTE CORONARY SYNDROMES IN THE FIRST HOURS OF SYMPTOMS ONSET
  13. New-Onset Atrial Fibrillation After Aortic Valve Replacement
  14. Clinical outcomes with on‐label and off‐label use of the transcatheter heart valve in the United States
  15. Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection
  16. Successful transradial retrieval of an embolized guidewire during transradial vascular access
  17. Stratification of Outcomes After Transcatheter Aortic Valve Replacement According to Surgical Inoperability for Technical Versus Clinical Reasons
  18. Impact of CMS coverage decision on access to transcatheter aortic valve replacement
  19. Antithrombotic Treatment in Transcatheter Aortic Valve Implantation
  20. Optimizing rotational atherectomy in high‐risk percutaneous coronary interventions: Insights from the PROTECT ΙΙ study
  21. TCT-417 Left Ventricular Assist Improves 90 Day Outcomes With Unprotected Left Main Coronary Intervention: Analysis From The Protect II Trial
  22. Predictors of J-point elevation in a cross sectional US cohort
  23. Presence of anti-viral and anti-parasitic antibodies and cardiovascular mortality: Insights from NHANES III
  24. ST-T Wave Abnormality in Lead aVR and Reclassification of Cardiovascular Risk (from the National Health and Nutrition Examination Survey-III)
  25. QRS Duration on Electrocardiography and Cardiovascular Mortality (from the National Health and Nutrition Examination Survey—III)
  26. Reversal of end stage renal disease in patient with transcatheter aortic valve replacement
  27. Non‐pharmacologic stroke prevention in atrial fibrillation
  28. Safety of transradial cardiac catheterization in patients with end‐stage liver disease
  29. Transseptal antegrade transcatheter aortic valve replacement for patients with no other access approach—A contemporary experience
  30. Electrocardiographic Abnormalities and Reclassification of Cardiovascular Risk: Insights from NHANES-III
  31. RACIAL DISPARITIES IN USE OF DRUG ELUTING STENT BETWEEN BLACKS AND WHITES IN THE STATE OF FLORIDA
  32. OBESITY IS ASSOCIATED WITH LOWER MORTALITY FOLLOWING ACUTE CORONARY SYNDROMES: A META-ANALYSIS
  33. IMPACT OF CMS COVERAGE DECISION ON ACCESS TO TRANSCATHETER AORTIC VALVE REPLACEMENT
  34. THE INCIDENCE OF ACUTE KIDNEY INJURY AFTER CARDIAC CATHETERIZATION OR PCI: A COMPARISON OF RADIAL VERSUS FEMORAL APPROACH
  35. TRANSSEPTAL ANTEGRADE TRANSCATHETER AORTIC VALVE REPLACEMENT FOR NO–ACCESS OPTION PATIENTS: A CONTEMPORARY EXPERIENCE
  36. NEW ONSET ATRIAL FIBRILLATION AFTER AORTIC VALVE REPLACEMENT: A COMPARISON OF TRANSFEMORAL TRANSAPICAL, TRANSAORTIC AND SURGICAL APPROACHES
  37. QRS DURATION ON ELECTROCARDIOGRAPHY AND CARDIOVASCULAR MORTALITY: INSIGHTS FROM NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY-III
  38. IMPACT OF ACUTE KIDNEY INJURY ON OUTCOMES IN PATIENTS UNDERGOING BALLOON AORTIC VALVULOPLASTY
  39. UTILIZATION AND MORTALITY TRENDS FOR BALLOON AORTIC VALVULOPLASTY IN THE UNITED STATES: A 8 YEAR PERSPECTIVE
  40. UTILIZATION AND MORTALITY TRENDS FOR BALLOON MITRAL VALVULOPLASTY IN THE UNITED STATES: AN EIGHT–YEAR PERSPECTIVE
  41. INCIDENCE OF STROKE IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT USING EDWARDS SAPIEN VALVE FOR CRITICAL AORTIC STENOSIS. META–ANALYSIS COMPARING TRANSFEMORAL VERSUS TRANSAPICAL APPROACH
  42. Faculty Opinions recommendation of Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.
  43. Faculty Opinions recommendation of Bariatric surgery and cardiovascular outcomes: a systematic review.
  44. TCT-875 Frailty is a Major Determinant of Length of Stay After Transcatheter Aortic Valve Replacement
  45. TCT-375 Optimizing Rotational Atherectomy in High-Risk Percutaneous Coronary Interventions. Insights from the PROTECT II study
  46. TCT-876 Decreasing B – Type Natriuretic Peptide Predicts Survival After Transcatheter Aortic Valve Replacement
  47. TCT-865 Rotational Aortography With CT Reconstruction Can Guide Transcatheter Aortic Valve Replacement And Predict Prosthetic Regurgitation
  48. TCT-886 Predictors of Vascular complications in patients undergoing Balloon Aortic Valvuloplasty
  49. Has the gender gap in percutaneous coronary intervention‐related mortality narrowed?
  50. Isolated Nonspecific ST-Segment and T-Wave Abnormalities in a Cross-Sectional United States Population and Mortality (from NHANES III)
  51. The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome
  52. Percutaneous retrograde left ventricular assist support for interventions in patients with aortic stenosis and left ventricular dysfunction
  53. PREDICTORS OF MAJOR BLEEDING POST BALLOON AORTIC VALVULOPLASTY: RESULTS FROM THE BRAVO (EFFECT OF BIVALIRUDIN ON AORTIC VALVE INTERVENTION OUTCOMES) STUDY
  54. COMPARISON OF BLEEDING DEFINITIONS, BARC, GUSTO, TIMI AND VARC IN PATIENTS UNDERGOING BALLOON AORTIC VALVULOPLASTY: RESULTS FROM A TWO-CENTER REGISTRY
  55. PREDICTORS OF NET ADVERSE CLINICAL EVENTS POST BALLOON AORTIC VALVULOPLASTY: RESULTS FROM THE BRAVO (EFFECT OF BIVALIRUDIN ON AORTIC VALVE INTERVENTION OUTCOMES) STUDY
  56. IMPACT OF BIVALIRUDIN ON ACCESS AND NON-ACCESS RELATED BLEEDING IN PATIENTS UNDERGOING BALLOON AORTIC VALVULOPLASTY: RESULTS FROM A 2-CENTER REGISTRY
  57. IMPACT OF VASCULAR CLOSURE WITH THE PRE-CLOSURE TECHNIQUE ON ADVERSE EVENTS IN PATIENTS UNDERGOING TRANSFEMORAL BALLOON AORTIC VALVULOPLASTY: RESULTS FROM A 2-CENTER registry
  58. Differences in Treatment Patterns and Outcomes Between Hispanics and Non-Hispanic Whites Treated for ST-Segment Elevation Myocardial Infarction
  59. The Kinetics of Integrilin Limited by Obesity: A multicenter randomized pharmacokinetic and pharmacodynamic clinical trial
  60. Therapeutic Goals in Patients with Refractory Angina
  61. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: Beyond aspirin and clopidogrel
  62. Dual Percutaneous Mechanical Circulatory Support as a Bridge to Recovery in Fulminant Myocarditis
  63. The impact of numeric and graphic displays of ST-segment deviation levels on cardiologists' decisions of reperfusion therapy for patients with acute coronary occlusion
  64. Percutaneous left ventricular assist devices—Still waiting for the final word
  65. A tale of two pressures: A case of pseudo‐prosthetic mitral valve stenosis
  66. HEMODYNAMIC SUPPORT WITH IMPELLA 2.5 IN HIGH-RISK INTERVENTIONS FOR PATIENTS WITH AORTIC STENOSIS
  67. KINETICS OF INTEGRILIN LIMITED BY OBESITY (KILO): A MULTI-CENTER RANDOMIZED CLINICAL TRIAL
  68. SAFETY OF TRANSRADIAL CARDIAC CATHETERIZATION IN PATIENTS WITH END-STAGE LIVER DISEASE
  69. Intracoronary Thrombus
  70. Anticoagulation in percutaneous coronary intervention
  71. Therapeutic Goals in Patients With Refractory Chronic Angina
  72. Metas terapéuticas en pacientes con angina refractaria crónica
  73. The Transradial Approach to Percutaneous Coronary Intervention
  74. FACTOR IXA INHIBITION WITH REG1 PROVIDES RAPID ONSET, STABLE AND ACTIVELY CONTROLLED ANTICOAGULATION DURING PCI
  75. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome
  76. Latinos’ sources of medication and medication information in the United States and their home countries
  77. Safety and Performance of Targeted Renal Therapy: The Be-RITe! Registry
  78. Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction
  79. Mitral Regurgitation
  80. Right Ventricular Myocardial Infarction
  81. Impact of Iodinated Contrast Injections on Percent Diameter Coronary Arterial Stenosis and Implications for Trials of Intracoronary Pharmacotherapies in Patients With ST-Elevation Myocardial Infarction
  82. Measuring and Treating Serum Lipids in Patients in a Chest Pain Observation Unit
  83. A case report of simultaneous thrombosis of two coronary artery stents in association with clopidogrel resistance
  84. Racial Differences Among High-Risk Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from the SYNERGY Trial)††Disclosure: Drs. Mahaffey, Cohen, Newby, Ferguson, and Califf have received honoria for speaking from sanofi...
  85. Mechanical thrombectomy options in complex percutaneous coronary interventions
  86. Regional Outcomes After Admission for High-Risk Non-ST-Segment Elevation Acute Coronary Syndromes
  87. Aortic counterpulsation: A review of the hemodynamic effects and indications for use
  88. A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization
  89. Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: Initial experience with intracoronary tenecteplase
  90. Clinical predictors and characteristics of patients with chronic liver disease and intrapulmonary shunts
  91. Drug-Eluting Stents in Acute Myocardial Infarction
  92. Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials
  93. Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction: Attractive Concept but Difficult to Prove!
  94. 1115-74 Screening for asymptomatic coronary artery disease in the potential renal transplant recipient
  95. 1112-146 Clinical predictors and characteristics of patients with intra-pulmonary shunts
  96. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase
  97. Transcutaneous ultrasound-facilitated coronary thrombolysis during acute myocardial infarction
  98. Local delivery of irinotecan with drug-eluting stents inhibits neointimal proliferation in hypercholesterolemic rabbits
  99. Sestamibi perfusion imaging predicts wall motion recovery beyond TIMI grade 3 flow following primary stenting
  100. Electrocardiographic comparison of myocardial salvage with primary revascularization versus thrombolysis in inferior myocardial infarction
  101. Successful percutaneous coronary intervention with stent implantation in anomalous right coronary arteries arising from the left sinus of valsalva: A report of two cases
  102. Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial
  103. Clinical, Electrocardiographic, and Biochemical Data for Immediate Risk Stratification in Acute Coronary Syndromes
  104. Outcomes following interventions in small coronary arteries with the use of hand-crimped Palmaz-Schatz stents
  105. The correlation between presenting ST-segment depression and the final size of acute myocardial infarcts in patients with acute coronary syndromes
  106. Outcome of hispanic patients treated with thrombolytic therapy for acute myocardial infarction